Larry Ellberger, Chairman

Principal and Founder, HVA, Inc.

Mr. Ellberger was appointed Chairman of the Board of Directors of Celldex in September 2009. Mr. Ellberger has been an independent member of the Celldex Board of Directors since the merger in March 2008 between Celldex and AVANT Immunotherapeutics, Inc., and was a member of the AVANT Board since 2003. He served as Chairman of the Board of Omrix Biopharmaceuticals, Inc. (which was purchased by Johnson and Johnson in 2008). In October 2005, Mr. Ellberger was appointed interim Chief Executive Officer of PDI, Inc., where he had been serving as a Director and Chairman of the Audit Committee. Mr. Ellberger was a Board member and Senior VP of Powderject PLC from 1999-2003. Prior to joining Powderject, Mr. Ellberger was an officer of W.R. Grace & Co. from 1995 to 1999, serving as Interim Chief Executive Officer in 1997-1998, Chief Financial Officer from 1996 and Senior Vice President, Strategic Planning and Development from 1995. From 1975 to 1995, Mr. Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice President, Corporate Development. In addition to his current position as Founding Partner of HVA, a healthcare transaction advisory firm, Mr. Ellberger is a Director of TransPharma Medical Ltd. and the Jewish Children’s Museum.